CL347 | 1510805-43-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: CL347
• 英文别名: 4-[[6-amino-2-(butylamino)-8-oxo-7H-purin-9-yl]methyl]-N-[2-[3-[4-[3-[3-[bis(3,7,11,15-tetramethylhexadecoxy)phosphoryl]propylamino]propylamino]butylamino]propylamino]-2-oxoethyl]benzamide
• CAS: 1510805-43-2
• 化学式: C₇₂H₁₃₄N₁₁O₆P
• 分子量: 1280.9
• InChiKey: AINBOPDHIOAORN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.1
• 重原子数：
  90.0
• 可旋转键数：
  58.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  231.7
• 氢给体数：
  8.0
• 氢受体数：
  15.0

反应信息

• 作为产物：
  描述：

  2-氯-6-氨基嘌呤 在 N-甲基吗啉 、 palladium 10% on activated carbon 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 水 、 氢气 、 溴 、 caesium carbonate 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 18.0~20.0 ℃ 、101.33 kPa 条件下， 反应 108.0h， 生成 CL347
  参考文献：
  名称：

  Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids

  摘要：

  公开号：

  EP2674170B1

文献信息

• SMC combination therapy for the treatment of cancer
  申请人：Children's Hospital of Eastern Ontario Research Institute Inc.

  公开号：US10441654B2

  公开（公告）日：2019-10-15

  The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

  本发明包括提高 SMC 治疗癌症疗效的方法和组合物。特别是，本发明包括用于组合疗法的方法和组合物，其中包括 SMC 和至少刺激一种或多种凋亡或免疫途径的第二种制剂。第二种药剂可以是免疫刺激化合物或溶瘤病毒等。
• SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
  申请人：Children's Hospital of Eastern Ontario Research Institute Inc.

  公开号：US20170239347A1

  公开（公告）日：2017-08-24

  The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
• [EN] IMMUNE STIMULATING NANOPARTICLE COMPOSITION<br/>[FR] COMPOSITION DE NANOPARTICULES DE STIMULATION IMMUNITAIRE
  申请人：[en]DANMARKS TEKNISKE UNIVERSITET

  公开号：WO2022200553A2

  公开（公告）日：2022-09-29

  The present invention relates to immune stimulating nanoparticle compositions, and their use in treatment of diseases and disorders, such as cancer. In particular, the present invention relates to nanoparticle compositions comprising a TLR7 agonist, such as 1V270.5